JPRN-jRCT1080222261未知Unknown
Takepron special drug use surveillance Gastroesophageal reflux disease with dyspepsia symptoms
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 15,000 人开始时间: 2013年10月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with heartburn or acid regurgitation at the start of Takepron administration* , or patients without heartburn and acid regurgitation, but with endoscopic findings classified as Los Angeles grade A-D at the start of Takepron therapy.
- •2. Patients with symptoms of dyspepsia (i.e., postprandial fullness, early satiation, epigastric pain, epigastric burning, upper abdominal bloating, nausea/vomiting, or belching) at the start of Takepron administration*
- •*These patients must have answered never, sometimes/mild, often/moderate, or frequent/severe on a 4-point scale questionnaire about subjective symptoms.
排除标准
- •1. Patients who have taken any proton pump inhibitors (including Takepron) within 4 weeks before the start of Takepron administration
- •2. Patients taking antidepressants
研究者
相似试验
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660
招募中
Unknown
Post-marketing Surveillance Protocol Number;CLCZ696A1402HypertensionJPRN-jRCT2031230283Sugigmoto Toshiya1,000
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
已完成
不适用
Special drug use results surveillance for the use of SIMPONI in ulcerative colitisulcerative colitisJPRN-UMIN000027542Janssen Pharmaceutical K.K.300
招募中
Unknown
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90